Implant Sciences: Final Piece Of The Puzzle In Place With TSA Approval [View article]
Muktikat - did u listen to the Implant conference call last night? DMJR has been very cooperative working with Implant delaying the due date of the debt. DMJR was waiting for TSA approval. Now that IMSC has that, DMJR knows revenues will ramp and it will restructure the debt in their favor.
Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
agree. I was in the queue to ask mangement on their protocol call why they felt the stock was trading at such a discount, but the call went to its time limit and my question never got asked.
Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
My apologies your short position has not generated a profit on this "SA Pump" that moved the stock a whole 2.56% today.
For your information Adventrx did not buy SythRx for "chicken feed" as their are large royalty payments due to SythRx investors based on the success of ANX-188. Here is a quote from CEO Brian Culley on what Adventrx has to offer to ANX-188 and what they are doing differently. - good luck to you.
CEO Culley: "Sure. It's a colorful product. Because it has the ability to improve blood flow, one could apply it in a lot of different settings. A prior sponsor of this product tested it into phase III in sickle cell disease. Now they made a handful of mistakes. You know, to their credit it was the first large-scale sickle cell trial ever done so there were bound some things that didn't work out well for them. But they also didn't enroll the number of patients that they had planned to enroll and they had some, what I believe are, design flaws in the protocol. So although they had some things stacked against them, they very nearly succeeded. They did show a benefit. They did show that you could reduce the duration of crisis and they nearly showed statistical significance with that. It wasn't enough to get the product approved and in fact, it ended up being something that they were not able to go forward with.
But for Adventrx, we feel that we are able to quite well define exactly what the errors were the first time it was tested. So we're looking to improve upon the original design. We've gone out into the community to find out what's changed since the study was done the first time so that we can do it and actually show that the benefit is statistically significant. So we're quite encouraged that the fact that there's been a demonstration that the drug is active and it has a benefit. But as it happens in clinical development, sometimes there are some mistakes that are made and I think we're going to be able to improve upon those. So we are now a vehicle for what I hope will be the final testing of this product in sickle cell disease patients."
Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
?? the market cap of the company is only 38 million. My target is conservative. 665 million market cap would be $13 / share based on 49 million shares outstanding. whats not to get?
ok I will sorry. I was trying to give you credit and get your article more hits. great research as usual. Great bullish article on DANG in buybuychinaonline today,
Why China Housing & Land Development Should Be Trading Substantially Higher [View article]
Why China Housing & Land Development Should Be Trading Substantially Higher [View article]
Why China Housing & Land Development Should Be Trading Substantially Higher [View article]
thanks
Why China Housing & Land Development Should Be Trading Substantially Higher [View article]
Implant Sciences: Final Piece Of The Puzzle In Place With TSA Approval [View article]
Good try shorty. This is Invision all over again!
Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
LONG
Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
For your information Adventrx did not buy SythRx for "chicken feed" as their are large royalty payments due to SythRx investors based on the success of ANX-188. Here is a quote from CEO Brian Culley on what Adventrx has to offer to ANX-188 and what they are doing differently. - good luck to you.
CEO Culley: "Sure. It's a colorful product. Because it has the ability to improve blood flow, one could apply it in a lot of different settings. A prior sponsor of this product tested it into phase III in sickle cell disease. Now they made a handful of mistakes. You know, to their credit it was the first large-scale sickle cell trial ever done so there were bound some things that didn't work out well for them. But they also didn't enroll the number of patients that they had planned to enroll and they had some, what I believe are, design flaws in the protocol. So although they had some things stacked against them, they very nearly succeeded. They did show a benefit. They did show that you could reduce the duration of crisis and they nearly showed statistical significance with that. It wasn't enough to get the product approved and in fact, it ended up being something that they were not able to go forward with.
But for Adventrx, we feel that we are able to quite well define exactly what the errors were the first time it was tested. So we're looking to improve upon the original design. We've gone out into the community to find out what's changed since the study was done the first time so that we can do it and actually show that the benefit is statistically significant. So we're quite encouraged that the fact that there's been a demonstration that the drug is active and it has a benefit. But as it happens in clinical development, sometimes there are some mistakes that are made and I think we're going to be able to improve upon those. So we are now a vehicle for what I hope will be the final testing of this product in sickle cell disease patients."
Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
http://bit.ly/Sql5BR
Dangdang: Accumulating Shares [View article]
Dangdang: Accumulating Shares [View article]
Your right they will probably never hire a new CFO
I recomnended investors cover their short position of SVVC from $45 at $27,and I recomended buy the stock at 19 and change.
Dangdang: Buy Opportunity [View article]
Your right they will probably never hire a new CFO
Dangdang: Accumulating Shares [View article]
Why I Think Dangdang Will Trade Over $750/Share In 5 Years [View article]
I will have a detailed eps analysis next week.